30 closest matches · ranked by relevance
Masseter Muscle Hypertrophy
Primary: Change From Baseline in Lower Facial Volume Using VECTRA 3D Images — -8.20; -7.41; -6.84; -4.40 cubic centimeter (cm^3) — p=< 0.001
Masseter Muscle Prominence
Primary: Achievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 90 — 2.2; 51.2 percentage of participants — p=<0.0001
Healthy Volunteers
Primary: Inter-rater Reliability Using a Masseter Muscle Prominence Scale (MMPS) — 0.728; 0.711 Kendall's W
Masseter Muscle Prominence
Primary: Percentage of Participants Who Achieved Masseter Muscle Prominence Scale (MMPS) Grade ≤ 3 at Day 90 as Assessed by the Investigator — 21.7; 90.6; 91.3 percentage of…
HIV Posterior Cheek Enlargement
Primary: Percentage Change in Volume of the Masseter Muscle From Baseline to 12 Weeks After Treatment With Botulinum Toxin A — 21.4 percentage reduction in masseter volume
Temporomandibular Joint Dysfunction Syndrome
Primary: Self Report of Pain — -.86; -2.0; -1.4; -1.3 Scores on pain intensity scale — p=0.17
Contour
Primary: Percentage of Participants Who Showed ≥ 1-point Jawline Improvement From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS), as Assessed by the…
Pain, Head · Pain Syndrome · Temporomandibular Disorder
Primary: Change in Jaw Pain as Reported by Patient on Visual Analog Scale (VAS) — 58; 54; -19; -14 score on a scale — p=0.80
Body Fat Disorder
Primary: Number of Participants With Unanticipated Adverse Device Effects (UADE) — 0 Participants with UADE reported
Jowls
Primary: Blinded Physician Jawline Rating Scale (JRS) Assessment on Scale of 0 to 4 at Baseline Versus 4 Weeks After Last Injection. — 2.214; 2.071; 1.857; 1.857 score on a scale…
Jawline Definition
Primary: Percentage of Responders Having At Least a 1-Grade Improvement From Baseline on Both Jawlines Concurrently Based on Galderma Jawline Scale (GJS) at Month 3 as Assessed…
Jawline Definition Deficiency
Primary: Percentage of Responders Based on Blinded Evaluators' Live Assessment of the Galderma Jawline Scale (GJS) — 14.3; 85.1 percentage of participants — p=<0.001
Improvement of Jawline Contour
Primary: Responder Rate According to the Merz Jawline Assessment Scale (MJAS) — 75.6; 8.8 percentage of participants — p=<0.0001
Myofascial Pain Syndrome · Temporomandibular Disorder
Primary: Changes of Perceived Pain Between Three Time Points (Baseline, Post-treatment, and 3 Months Later) and Between Groups (Sham Simulation and Pressure Release Technique)…
Body Fat Disorder
Primary: The Proportion of Subjects Who Have at Least a 1-grade Improvement on the Clinician Reported Submental Fat Rating Scale (CR-SMFRS) at the Final Follow-up Visit When…
Volume Loss of the Jawline
Primary: Percentage of Jawlines Achieving Greater Than or Equal to (>=) 1-point Improvement on Merz Jawline Grading Scale (MJGS) at Week 4 — 92.1; 0; 92.1; 0 percentage of…
Impacted Third Molar Tooth · Temporomandibular Disorder
Primary: Occurrence of Pain at Follow-up With Wide Opening, or Pain in the Temple, Jaw Joint or Jaw Muscles. — 26; 32; 54; 53 Participants
Skin Laxity
Primary: Improvement in Overall Lifting and Tightening of Skin — 48 percentage of participants improved
Perioral Rejuvenation · Upper Lip Projection
Primary: Nasal Tip Projection — 0.601 ratio
Swelling
Primary: Effect of Perioperative Steroid for the Postoperative Swelling After Orthognathic Surgery — 167.06; 190.73; 61.39; 57.62 ml — p=>0.05
Chin Retrusion
Primary: Percentage of Participants With a ≥ 1-point Improvement (Decrease) on the Allergan Chin Retrusion Scale (ACSR) Score — 56.3; 27.5 percentage of participants — p=0.0019
Oral Cancer
Primary: TheraBite Range-of-Motion Scale — 27.43; 26.57; 27.33; 16.17 units on a scale
Jawline Definition
Primary: Percentage of Participants Who Show ≥ 1-point Jawline Improvement on Both Sides From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS) — 38.0; 69.0…
Smiling · Botulinum Toxins, Type A
Primary: Anterior Gingival Exposure (GE) 4 Weeks Post-injection — 3.6; 3.0 mm
Peripheral Nerve Facial Nerve Paralysis · Facial Nerve Diseases · Orofacial Pain
Primary: The Visual Analog Scale for Pain Was Used to Grade Discomfort in Chewing After the Installation of Facial Paralysis. Level Zero is the Lack of Discomfort and 10 is the…
Bruxism · Sleep Bruxism, Adult · Awake Bruxism
Primary: Pain Intensity Measured by Visual Analog Scale (VAS) — 8.909; 8.957; 9.167; 1.591 VAS score (0-10)
Microstomia · Systemic Sclerosis
Primary: Change From Baseline in Oral Aperture Measurement — 32.98; 32.92; 33.40; 34.37 milimeters — p=0.564
Malar Deficiency
Primary: Blinded Evaluations of First Impression — 7.35 score on a scale
Mild to Moderate Skin Laxity on Cheek · Mild to Moderate Skin Laxity on Upper Neck · Mild to Moderate Subcutaneous Fat on Cheek
Primary: Change in Overall Lifting and Tightening of Treated Tissue on the Lower Face and Submental Regions. — 68.60 percentage of participants improved
Temporomandibular Joint Disorders · Orofacial Pain
Primary: Visual Analogic Scale for Pain Intensity (0-10) — 6.52; 4.8; .81; 2.05 units on a scale